Product overview 2011
Diagnostics
Index BioPorto® Diagnostics The NGAL Test™ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . NGAL ELISA Kit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Rapid NGAL ELISA Kit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Animal NGAL ELISA Kits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . APC-PCI ELISA Kit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . MBL Oligomer ELISA Kit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3 5 6 7 8 9
AntibodyShop® Cell biology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Coagulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Collectins and related products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Complement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cytokines and hormones . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Enzymes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Marker molecules . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Microbiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Miscellaneous . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Other blood proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Sera and antigens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Abbreviations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10 11 11 11 13 14 14 14 15 15 15 16 16
Alphabetical product index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Ordering information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
ABOUT US BioPorto develops and markets antibodies and antibody-based products, including tests to diagnose human disease, both for the benefit of individual patients and to promote efficiency in the health sector. The Company’s developments include a test (NGAL) to diagnose and monitor acute kidney damage.
QUALITY POLICY BioPorto Diagnostics is committed to the highest level of quality in the manufacture, sale and support of its products. Quality and compliance with all applicable regulatory requirements and customer satisfaction must underlie the company’s efforts in manufacturing, advertising, sales, shipping and technical support.
BioPorto was founded in 2000 and is listed on NASDAQ OMX Copenhagen (symbol: BIOPOR).
BioPorto Diagnostics is committed to effectively implementing and continuously improving its quality management system in accordance with the European IVD directive, the Canadian medical device regulations and ISO 13485 requirements. BioPorto is ISO 13485:2003 certified and holds an ISO 13485:2003 certificate under CMDCAS.
Within the Company’s focus areas, BioPorto’s strategy is to develop new methods that can be patented and achieve a wide use in the diagnosis of various diseases.
BioPorto Diagnostics aims to please the customers while paying due regard to the interests of the company’s stakeholders.
2 Diagnostics
The NGAL Test™ – NGAL: changing the diagnosis and management of acute kidney injury (AKI) NGAL is a biomarker for diagnosing acute kidney injury (AKI). Its key advantage is that it responds earlier than other renal status markers like serum creatinine and shows a proportionate response to injury. The NGAL Test™ is a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine and EDTA plasma on automated clinical chemistry analyzers. NGAL measurements are useful in the diagnosis of acute kidney injury which may lead to acute renal failure. Using only a few drops of plasma or urine The NGAL Test™ gives you results in just 10 minutes and thus addresses the widespread demand for fast NGAL results.
3
Cat. No.
Product name
Contents
st001ca
IVD
The NGAL Test Reagent Kit
Immunoparticle Suspension, 7 mL Reaction Buffer, 35 mL
ST002CA
IVD
The NGAL Test™ Calibrator Kit
5 vials of 1 mL Prediluted calibrators
ST003CA
IVD
The NGAL Test™ Control Kit
6 vials of 1 mL Control Low, 3 x1 mL Control High, 3 x1 mL
Diagnostics
™
Clinical application · · · ·
Intensive care - monitoring Emergency room - triage tool Renal transplantation predictive evaluation Intravenous contrast agents assesing nephrotoxicity
Assay specifications Method
Particle-enhanced turbidimetric immunoassay
Sample
Urine and EDTA plasma
Sample stability
If the assay cannot be performed within 24 hours or specimens are to be shipped, freeze the specimens at −20°C or below. For long-term storage of specimens, −70°C or below is recommended.
Calibrators
5 vials: 150, 600, 1500, 3000 and 5000 ng/mL Liquid ready-to-use
Controls
Low (200 ng/mL) and High (500 ng/mL) controls Liquid ready-to-use
Assay time
10 minutes
Shelf life
12 months
Open vial stability
30 days
On board stability
30 days (when refrigerated)
Measuring range
25 to 5000 ng/mL
LIMITATION The NGAL Test™ is meant to aid the diagnosis of kidney injury which may lead to acute renal failure. However, The NGAL Test™ is not a stand-alone test as a variety of independent pathologies are associated with raised levels of urinary or plasma NGAL. Physicians must interpret the significance of any raised NGAL level in the light of the patient’s clinical features. For in vitro diagnostic use in selected countries only. See www.bioporto.com for availability in your country. Diagnostic use patented/patent pending in selected countries, WO2006066587. See www.bioporto.com for an updated list of issued and pending patents.
4 Diagnostics
NGAL ELISA Kit – The preferred assay for NGAL measurement in laboratory research With the NGAL ELISA Kit (KIT 036), urine, plasma or serum samples can be analyzed with conventional ELISA equipment. Cat. No.
Product name
Size
KIT 036
NGAL ELISA Kit
96 wells
WASH 036-30
25x Wash Solution Concentrate for KIT 036
30 mL
WASH 036-250
25x Wash Solution Concentrate for KIT 036
250 mL
Key features · · · · · · · · ·
5
Diagnostics
4-hour assay format Simple ELISA format - easy to perform Ready-to-use calibrators and working solutions Pre-coated ELISA strips All incubations performed at room temperature Easy storage All components are stored at 4°C Automation possible on open ELISA workstations For Research Use Only. Not for use in diagnostic procedures
NGAL Rapid ELISA Kit
†
IVD
*
– NGAL: the early biomarker for diagnosing acute kidney injury (AKI) Cat. No.
Product name
Size
KIT 037
NGAL Rapid ELISA Kit
96 wells
WASH 037-30
25x Wash Solution Concentrate for KIT 037
30 mL
WASH 037-250
25x Wash Solution Concentrate for KIT 037
250 mL
Key features · · · · · · · · ·
1 hour rapid assay format Simple ELISA format - easy to perform Ready-to-use calibrators and working solutions Pre-coated ELISA strips All incubations performed at room temperature Easy storage All components are stored at 4°C Automation possible on open ELISA workstations Assay dynamic range is 100-fold (0.2 – 20 ng/mL)
*For in vitro diagnostic use in selected countries only. See www.bioporto.com for availability in your country. Diagnostic use patented/patent pending in selected countries, WO2006066587. See www.bioporto.com for an updated list of issued and pending patents.
†
6 Diagnostics
Animal NGAL ELISA Kits Evidence is rapidly accumulating to show that NGAL also rises in animals after kidney injury as in humans, where NGAL undergoes an early and dramatic up-regulation in renal tubular cells after kidney injury from a variety of causes. NGAL is then released into both urine and plasma and can be used in basic research, medical research as well as in preclinical drug development studies, to detect the extent of kidney injury.
7
Cat. No.
Product name
Size
KIT 042
Mouse NGAL ELISA Kit
Up to 40 samples in duplicate
KIT 043
Dog NGAL ELISA Kit
Up to 40 samples in duplicate
KIT 044
Pig NGAL ELISA Kit
Up to 41 samples in duplicate
KIT 045
Monkey NGAL ELISA Kit
In development
KIT 046
Rat NGAL ELISA Kit
Up to 40 samples in duplicate
Diagnostics
Key features · · · · · · · ·
Highly reproducible and easy to use Ready-to-use working solutions Ready-to-use calibrators Pre-coated 96-well ELISA plate All incubations performed at room temperature Easy storage All components are stored at 4°C Requires only standard ELISA equipment
APC-PCI ELISA Kit – APC-PCI: a potential marker for evaluating sepsis patients for APC treatment Activated protein C-protein C inhibitor (APC-PCI) complex starts being formed as soon as protein C (PC) is activated on the blood vessel wall and the active enzyme (APC) enters into contact with its specific circulating serpin, protein C inhibitor (PCI). The resulting inactive APC-PCI complex is thus a marker of PC activation. Sepsis is a devastating condition characterized by systemic activation of the inflammatory and coagulation cascades in response to microbial infection. Apart from antimicrobial therapy, the infusion of human recombinant APC (Xigris®, Eli Lilly) is the only treatment documented to reduce the mortality of sepsis patients.
Key features
BioPorto Diagnostics’ APC-PCI ELISA Kit measures activated protein C–protein C inhibitor complex in human plasma. For Research Use Only. Not for use in diagnostic procedures.
·
Cat. No.
Product name
Size
KIT 040
APC-PCI ELISA Kit
96 wells
· ·
·
Highly reproducible and easy to use Precoated microwell strips that can be used as strips of 8 or as individual wells All incubations performed at room temperature Only standard ELISA equipment is required
8 Diagnostics
MBL Oligomer ELISA Kit
IVD
*
– a key test in the assessment of primary immunodeficiency Mannan-binding lectin (MBL) is an important component of the innate immune system. However, in at least 12% of the average Caucasian population, the circulating level of functional MBL is insufficient. This makes MBL deficiency by far the most common primary immunodeficiency. While the consequences of MBL deficiency can be quite subtle, several studies have shown that MBL deficiency increases susceptibility to infectious diseases and predisposes to greater severity when infections occur. The MBL Oligomer ELISA Kit employs a monoclonal antibody sandwich which is highly specific for normally oligomerized MBL molecules. Hence the results obtained with the KIT 029 correspond to the circulating levels of “functional” MBL. Cat. No.
Product name
Size
KIT 029
MBL Oligomer ELISA Kit
96 wells
WASH 029-30
25x Wash Solution Concentrate KIT 029
30 mL
WASH 029-250
25x Wash Solution Concentrate KIT 029
250 mL
* For in vitro diagnostic use in selected countries only. See www.bioporto.com for availability in your country.
9
Diagnostics
Key features · · · · ·
Measures oligomerized “functional” MBL Measures in plasma and serum All reagents are ready-to-use Storage at 2-8°C Can be used in many different automated ELISA workstations
Monoclonal antibodies Antibodies are listed according to their antigen by product area and with information about package size, applications, catalog number and conjugation, when applicable. All the antibodies are protein-A or protein-G purified and the unconjugated antibodies are delivered in a concentration of 1 mg/mL in 10 mM phosphate buffer, pH 7.4, containing 0.5 M sodium chloride and 15 mM sodium azide as preservative. Conjugated antibodies are delivered at a concentration of 1 mg/mL in 10 mM phosphate buffer, pH 7.4, containing 0.14 M NaCl and 15 mM sodium azide. If the antibody you are looking for has more than one clone, please visit our website www.bioporto.com/products or feel free to contact us at info@bioporto.com.
Cell biology
Perlecan CSI 001
Thrombospondin I
Tetranectin
Collagen I, III & V
HYB 130
CSI 006 CSI 007 CSI 008
Vitronectin
Fibronectin
CSI 002
CSI 003 CSI 004
CSI 005 HYB 051
Specificity
Application
Cat. No.
Collagen Type I (human, bovine, pig, sheep, dog, goat)
EL, WB, IH
CSI 008-01
Collagen Type III (human, dog, rat, kangaroo)
EL, WB, IH
CSI 007-01
Collagen Type V (human, dog, sheep, pig, kangaroo, rabbit, bovine)
EL, WB, IH
CSI 006-01
Fibronectin (bovine)
EL, WB, IH, IP
CSI 005-22
Fibronectin (bovine, human)
EL, WB, IH, IP
>1 clone
Fibronectin (bovine, human, chicken)
EL, WB, IH, IP
CSI 005-17
Fibronectin (human)
EL, WB
HYB 051-05
Perlecan (bovine)
EL, IH, IP, AC, WB
>1 clone
Tetranectin (human)
EL, WB, IH
>1 clone
Thrombospondin I (bovine)
EL, IH, IP
CSI 002-65
Vitronectin (bovine, horse, rabbit)
EL, IH
CSI 004-18
Vitronectin (bovine, sheep)
EL, WB, IH, AP
CSI 004-27
Vitronectin (human)
EL, WB, IH
>1 clone
Vitronectin (human, dog, cat, rabbit, bovine)
EL, WB
CSI 003-21
Vitronectin (human, dog, cat, sheep)
EL, WB
CSI 003-08
10
Coagulation Specificity
Application
Cat. No.
Antithrombin III (human)
EL, WB
>1 clone
Antithrombin III (human, denatured)
EL, WB
HYB 228-12
Antithrombin III (human, native and denatured)
EL, IH
HYB 228-08
APC–AAT complexes, neoepitope (human)
EL
ABS 001-07
Aprotinin
EL, WB
>1 clone
Aprotinin, Biotinylated
EL
ABS 037-18B
D-dimer (human, dog)
EL
>1 clone
D-dimer (human, dog), Biotinylated
EL
ABS 015-22B
Factor IX (human, Christmas factor)
EL, WB
>1 clone
Fibrinogen (human)
EL, WB
>1 clone
Hirudin
EL, WB
>1 clone
Protein C (human)
EL, WB, IH
>1 clone
Protein S (human)
EL
HYB 232-11
Thrombin (human)
EL, WB
>1 clone
von Willebrand factor (human, vWf)
EL
>1 clone
Specificity
Application
Cat. No.
Collectin-43 (bovine, CL-43)
EL, WB
>1 clone
Conglutinin (bovine)
EL
HYB 263-02
H-Ficolin (human)
EL
RIG 334-01
H-Ficolin (human), Biotinylated
EL
RIG 334-01B
Glycoprotein-340 (human, gp-340)
EL, WB, IH
>1 clone
L-Ficolin (human)
EL, WB
>1 clone
M-Ficolin (human)
EL, IH
>1 clone
Surfactant protein A (human, hSP-A)
EL, WB, IH
HYB 238-04
Surfactant protein a (human, hSP-A), Biotinylated
EL
HYB 238-04B
Surfactant protein D (human, hSP-D)
EL, WB, IH
>1 clone
Surfactant protein D (human, hSP-D), Biotinylated
EL
HYB 246-04B
Specificity
Application
Cat. No.
Complement component C1-inhibitor (C1-INH)
EL
>1 clone
Complement component C1s (human, pro- and activated enzyme)
EL
>1 clone
Complement component C2 (human)
EL, WB
>1 clone
Complement component C3 (human)
EL, WB
>1 clone
Complement component C3 (human), beta-chain genetic variant
EL, WB
HAV 004-01
Complement component C3 (rat)
EL, IH
HYB 118-02
Complement component C3a/C3a desArg (human)
EL, WB
>1 clone
Complement component C3a/C3a desArg (human), Biotinylated
EL
GAU 017-01B
Complement component C4 (human)
EL, WB
>1 clone
Complement component C5 (human)
EL, WB
>1 clone
Complement component C5a/C5a(desArg) anaphylatoxin (human)
EL, WB
GAU 025-05
Collectins and related products
Complement
11
Complement (continued) Specificity
Application
Cat. No.
Complement component C5b-9
EL, IH
DIA 011-01
Complement component C5b-9, Biotinylated
EL
DIA 011-01B
Complement component C9 (human)
EL, WB
>1 clone
Complement factor B (caiman)
EL, WB
KSK 002-01
Complement factor B (chicken)
EL, WB
HYB 022-03
Complement factor B (human)
EL, WB
>1 clone
Complement factor B (human), Biotinylated
EL
HYB 008-06B
Complement factor D (human)
EL, WB
>1 clone
Complement factor D (human), Biotinylated
EL
GAU 008-01B
Complement factor H (human, ß1H-globulin)
EL, WB
>1 clone
Complement factor H (human, ß1H-globulin), Biotinylated
EL
>1 clone
Complement factor I (human)
EL, WB
>1 clone
Mannan-binding lectin (chicken, MBL)
EL, WB, IH
HYB 182-01
Mannan-binding lectin (human, horse, pig, MBL)
EL
HYB 131-14
Mannan-binding lectin (human, MBL)
EL, WB, IH
>1 clone
Mannan-binding lectin (human, MBL), Biotinylated
EL
HYB 131-01B
Mannan-binding lectin (rat, MBL)
EL
HYB 131-18
Properdin (human)
EL, WB
>1 clone
Properdin (human), Biotinylated
EL
HYB 039-04B
MBL
Classical Pathway
KIT 029 HYB 131
Lectin Pathway
H-Ficolin
Alternative Pathway
RIG 334
M-Ficolin ABS 036
C1-INH HYB 288
L-Ficolin C1q
ABS 005
MBL/Ficolin
C1q
B H2O
C1s
C1r
C1s
ABS 002
C3 (H2O)
MASP-2
MASP-1
C3
C3 (H2O) B
Carbohydrate
Carbohydrate
C2
D
C4
C3 (H2O) Bb
C3
HAV 004 HYB 005
C3a
C2b
HAV 005
Factor D GAU 010 GAU 008
HYB 050 C2
Factor B
C4a
Ba
Factor Ba/b HYB 008
Properdin (Factor P)
Properdin HYB 039 3
C3d
HAV 003 HYB 030
C4b2a
C2a
C4b C3bBb
C4
HYB 162-04
C3a/C3a (desArg)
C3
GAU 013 GAU 017
C5
C4b
C3a
C3a
HYB 162-02
C3bBb3b
C4b2a3b
HYB 029
C5a/C5a (desArg) GAU 025
C5 - C9 Membrane attack complex
HYB 268 GAU 018 GAU 020
C9
ABS 004
C5b-9
DIA 011
Factor H
Lysis or phagocytosis of the microorganism Factor I HYB 061
Overview of the complement system. The name of the component and BioPorto Diagnostics' catalog number are shown in the blue boxes.
12
Cytokines and Hormones
Glucagon-like peptide-1 (C-terminal amidated) HYB 147-08 HYB 147-12 HYB 147-13
ABS 033-04 ABS 033-10
HYB 011-05 N-terminal extension
HYB 147-06 ABS 046-03
HYB 011-05
N-terminus
ABS 033-04 C-terminus ABS 033-10
C-terminus
1 1
N-terminal extension
6 7
2
HYB 011-05
7 3
HYB 011-05
ABS 9033-041 ABS 033-10
1
37
6 7
36 amide
37
36 amide
37
N-terminus
6 7
HYB 147-08 HYB 2 147-12 HYB 147-13
HYB 147-06
7
C-terminus
2
GLP-1 Active form
6 7
3
GLP-1 Metabolite 9
7
36 (amide)
Specificity
Application
Cat. No.
Adrenomedullin (human)
EL
ABS 027-01
EL, IH
>1 clone
EL, WB
>1 clone
Estradiol-17-beta
EL
HYB 057-02
Exendin-4
EL
>1 clone
EL
>1 clone
Gastric Inhibitory Polypeptide (GIP)
EL, IH
>1 clone
Ghrelin (human)
EL
ABS 050-45
Ghrelin (human, rat)
EL
ABS 052-121
Ghrelin (human, rat), Biotinylated
EL
ABS 052-121B
Glucagon-like peptide-1 (GLP-1(1-36)amide, N-terminal-extension specific)
EL
HYB 011-05
Glucagon-like peptide-1 (GLP-1(7-36)amide, C-terminal specific)
EL, IH
HYB 147-06
Glucagon-like peptide-1 (GLP-1(7-36)amide, C-terminal specific), Biotinylated
EL
HYB 147-06B
Glucagon-like peptide-1 (GLP-1(7-37) and GLP-1(7-36)amide, N-terminal specific)
EL, IH
>1 clone
Glucagon-like peptide-1 (GLP-1(7-37) and GLP-1(7-36)amide, N-terminal specific), Biotinylated
EL
ABS 033-10B
Glucagon-like peptide-1 (GLP-1, Mid-molecule specific)
EL, WB, IH
>1 clone
Glucagon-like peptide-1 (GLP-1, Mid-molecule specific), Biotinylated
EL
>1 clone
Glucagon-like peptide-1 (GLP-1, Non-amidated (-Arg-Gly), C-terminal specific)
EL
ABS 046-03
Glucagon-like peptide-1 (GLP-1, Non-amidated (-Arg-Gly), C-terminal specific), Biotinylated
EL
ABS 046-03B
Glucagon-like peptide-2 (human, GLP-2)
EL
HYB 006-02
Leptin
EL, IH
>1 clone
Leptin, Biotinylated
EL
ABS 022-11B
Neuropeptide Y (human, rat, mouse, NPY)
EL, IH
ABS 028-08
Pancreatic Polypeptide (human, PP)
EL
ABS 030-06
2
3
alpha-calcitonin gene-related peptide (alpha-CGRP)
7
Chorionic gonadotrophin (human, hCG)
9
3
Exendin-4, Biotinylated
13
36
HYBamide 147-08 HYB 147-12 HYB 147-13
N-terminus
GLP-1 Extended form 1
N-terminal extension
ABS 044-491 ABS 044-53
N-terminal extension
ABS 033-04 1 ABS 033-10 1
N-terminus
9
36 (amide)
36 (amide)
HYB 1 HYB 1 HYB 1
Cytokines and Hormones (continued) Specificity
Application
Cat. No.
Peptide Histidine-Methionine (PHM)
EL
ABS 020-03
Peptide YY (human, PYY (3-36)(peptide tyrosine-tyrosine amide, 3-36))
EL
ABS 051-04
Peptide YY (human, PYY)
EL, IH
ABS 029-01
Peptide YY (human, PYY), Biotinylated
EL
ABS 029-01B
Tumor necrosis factor alpha (human, TNF-alpha)
EL
>1 clone
Vasoactive Intestinal Peptide (human, bovine, porcine, rat, VIP)
EL
ABS 023-02
Specificity
Application
Cat. No.
Alkaline phosphatase (AP)
EL
HYB 252-08
Trypsin (human)
EL, WB
>1 clone
Trypsin (human), Biotinylated
EL
HYB 021-03B
Specificity
Application
Cat. No.
alpha-Fetoprotein (human, AFP)
EL
>1 clone
Acetylcholinesterase (bovine brain, AChE)
EL, WB
HYB 101-03
Acetylcholinesterase (human brain, AChE)
EL, WB
HYB 111-05
Acetylcholinesterase (human brain, bovine brain, AChE)
EL, WB
HYB 190-01
Amyloid beta-peptide (human)
EL, AP
>1 clone
Butyrylcholinesterase (human, BtChE)
EL
HAH 002-01
Neutrophil gelatinase-associated lipocalin (dog, NGAL)
EL, WB
>1 clone
Neutrophil gelatinase-associated lipocalin (dog, NGAL), Biotinylated
EL
ABS 047-14B
Neutrophil gelatinase-associated lipocalin (human, NGAL)
EL, WB, IH
>1 clone
Neutrophil gelatinase-associated lipocalin (human, NGAL), Biotinylated
EL
>1 clone
Neutrophil gelatinase-associated lipocalin (monkey, human, NGAL)
EL
ABS 038-23
Neutrophil gelatinase-associated lipocalin (mouse, NGAL)
EL, WB
>1 clone
Enzymes
Marker molecules
Neutrophil gelatinase-associated lipocalin (mouse, NGAL), Biotinylated
ABS 043-29B
Neutrophil gelatinase-associated lipocalin (pig, NGAL)
EL, WB
>1 clone
Neutrophil gelatinase-associated lipocalin (pig, NGAL), Biotinylated
EL
ABS 048-28B
Neutrophil gelatinase-associated lipocalin (rat, NGAL)
EL, WB, IH
>1 clone
Neutrophil gelatinase-associated lipocalin (rat, NGAL), Biotinylated
EL
ABS 039-32B
Placental protein 14 (human, PP14, glycodelin A)
EL, IH
>1 clone
Pregnancy-associated plasma protein A (human, PAPP-A)
EL, IH
>1 clone
Procollagen type I C-terminal propeptide (human, PICP)
EL
>1 clone
Procollagen type IIA N-terminal propeptide (human, PIIANP)
EL, IH
BTE 003-02
Specificity
Application
Cat. No.
Clostridium botulinum E toxoid (Botulin E toxoid)
EL
HAV 001-06
Clostridium tetani toxoid (Tetanus toxoid)
EL
>1 clone
Corynebacterium diphtheriae toxoid (Diphtheria toxoid)
EL, WB
>1 clone
Influenza A virus matrix protein
EL, WB
HYB 156-02
Influenza A virus matrix protein, Biotinylated
EL
HYB 156-02B
Microbiology
14
Microbiology (continued) Specificity
Application
Cat. No.
Influenza A virus nucleoprotein
EL, WB
HYB 156-01
Influenza A virus nucleoprotein, Biotinylated
EL
HYB 156-01B
Influenza B virus nucleoprotein
EL, WB
>1 clone
Influenza B virus nucleoprotein, Biotinylated
EL
HYB 116-03B
Mycobacterium tuberculosis Ag85
EL, WB
HYT 27-1
Mycobacterium tuberculosis, ESAT-6
EL, WB
HYB 076-08
Mycobacterium tuberculosis, L-alanine dehydrogenase (Ald)
EL, WB
HBT 10-1
Nitrobacter hamburgensis nitrite oxidoreductase
EL, WB, IH
>1 clone
Pneumolysin
EL, WB
HYB 041-01
Poliovirus type 1
EL
>1 clone
Poliovirus type 2
EL
>1 clone
Poliovirus type 3
EL
>1 clone
Streptolysin
EL
HAB 003-1
Specificity
Application
Cat. No.
Amodiaquine
EL
HYB 320-04
Atrazine
EL
HYB 225-01
Biotin
EL, WB
HYB 212-01
Chloroquine
EL
HYB 317-01
Gliadin peptide
EL
>1 clone
Immunoglobulin heavy chain (chicken, IgY)
EL, WB
HYB 208-03
Immunoglobulin light chain (rat, kappa chain)
EL, AC
MARK 1-1
MHC class I alpha chain (chicken)
WB
KSK 001-03
MHC class II beta chain (chicken)
WB, IH, FC, AP
KSK 001-02
Ovalbumin (chicken)
EL, IP
>1 clone
Ovalbumin (chicken, denatured)
EL, WB
>1 clone
Thioguanine (2-amino-6-mercaptopurine)
EL
>1 clone
Specificity
Application
Cat. No.
Plasminogen activator inhibitor type I (human, PAI-1)
EL, WB, IH, AP
>1 clone
Tissue plasminogen activator (human, tPA)
EL, WB, IH
MON T-1
Urokinase plasminogen activator (human, uPA)
EL, WB, IH, FC
>1 clone
Urokinase plasminogen activator receptor (human, uPAR)
EL, WB, IH, FC
>1 clone
Specificity
Application
Cat. No.
alpha1-Antitrypsin (human, alpha1- AT)
EL, WB
HYB 185-02
alpha1-Antitrypsin (human, alpha1- AT, native and denatured)
EL, WB
HYB 191-01
Albumin, bovine serum (BSA)
EL, WB
HYB 267-01
Albumin, bovine serum (BSA, denatured)
EL
HYB 261-02
Albumin, human serum (HSA)
EL, WB
>1 clone
Miscellaneous
Oncology
Other blood proteins
15
Other blood proteins (continued) Specificity
Application
Cat. No.
Albumin, human serum (HSA, denatured)
EL, WB
HYB 189-01-CS*
Albumin, human serum (HSA, denatured)
EL, WB
HYB 189-09
Apolipoprotein A-1 (human)
EL, WB
HYB 069-01
Apolipoprotein B (human)
EL, WB
>1 clone
beta2-Microglobulin (caiman)
WB
KSK 003-01
beta2-Microglobulin (human)
EL, AP
HYB 290-03
Gc-globulin (human)
EL, WB
>1 clone
Gc-globulin (human), Biotinylated
EL
>1 clone
Gelsolin (human)
EL, WB
ABS 017-20
Haptoglobulin (human)
EL
HYB 170-06
Hemopexin (human)
EL
ABS 013-32
Hemopexin (human), Biotinylated
EL
>1 clone
MDA-treated low-density lipoprotein (human, LDL)
EL, WB
>1 clone
Sera and Antigens Specificity
Cat. No.
Human IgE (non-immune), without azide
DIA HE1
Human IgE (non-immune), with azide
DIA HE1A
Human IgE (non-immune), biotinylated
DIA HE1B
MBL standard serum (human) - 1000 (AU)
SER 101
MBL oligomer deficient serum, B/B genotype (human)
SER 102
SDS-PAGE (16%). Lane 1: Shows molecular weight markers. Lane 2: DIA HE1 purified human IgE, 185 kDa. Lane 3: IgE, purified from serum from a myeloma patient.
Human IgE (non-immune) DIA HE1
The DIA HE1 IgE preparation is an affinity-purified, fully human IgE antibody with kappa light chains. The IgE is produced in vitro from a monoclonal hybridoma. This unique source guarantees freedom from contamination by other immunoglobulin isotypes. Due to its very low batch-to-batch variation, this antibody is suitable as a standard in quantitative IgE assays, used in the field of allergy treatment and diagnostics. Other applications include research in immunochemistry and cellular immunology.
Abbreviations AC
Affinity chromatography
AP
Affinity purification
EL
Enzyme-linked immunosorbent assay (ELISA)
FC
Flow cytometry
IH
Immunohistochemistry
IP
Immunoprecipitation
WB
Western blotting
*Only available as a culture supernatant
16
Alphabetical product index ELISA kits and monoclonal antibodies listed by specificity A α-Fetoprotein (human, AFP) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 α1-Antitrypsin (human, α1-AT) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 α1-Antitrypsin (human, α1-AT, native and denatured) . . . . . . . . . . 15 α-Calcitonin gene-related peptide (α-CGRP) . . . . . . . . . . . . . . . . . 13 Acetylcholinesterase (bovine brain, AChE) . . . . . . . . . . . . . . . . . . . . 14 Acetylcholinesterase (human brain, AChE) . . . . . . . . . . . . . . . . . . . . 14 Acetylcholinesterase (human brain, bovine brain, AChE) . . . . . . . 14 Activated protein C-protein C inhibitor (APC-PCI) . . . . . . . . . . . . . . 8 Activated protein C-α1-antitrypsin, neoepitope (human) . . . . . . . . 11 Adrenomedullin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Albumin, bovine serum (BSA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Albumin, bovine serum (BSA, denatured) . . . . . . . . . . . . . . . . . . . . 15 Albumin, human serum (HSA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Albumin, human serum (HSA, denaturated) . . . . . . . . . . . . . . . . . . 16 Alkaline phosphatase (AP) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 2-amino-6-mercaptopurine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Amodiaquine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Amyloid-β peptide (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Antithrombin III (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Antithrombin III (human, denatured) . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Antithrombin III (human, native and denatured) . . . . . . . . . . . . . . . . 11 APC-AAT complexes, neoepitope (human) . . . . . . . . . . . . . . . . . . . . 11 APC-PCI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Apolipoprotein A-1 (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Apolipoprotein B (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Aprotinin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Atrazine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
D D-dimer (human, dog) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 DBP (human, Vitamin-D binding protein) . . . . . . . . . . . . . . . . . . . . . 16 Diphtheria toxoid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Dog NGAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 14
E Estradiol-17β . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Exendin-4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
F
B β1H-globulin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 β2-Microglobulin (caiman) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 β2-Microglobulin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Biotin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Botulin E toxoid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 BSA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 BSA, denatured . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Butyrylcholinesterase (human, BtChE) . . . . . . . . . . . . . . . . . . . . . . . . 14
C Calcitonin-gene related peptide (human, CGRP) . . . . . . . . . . . . . . 13 Chloroquine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Chorionic gonadotrophin (human, hCG) . . . . . . . . . . . . . . . . . . . . . . 13 Christmas factor (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Clostridium botulinum E toxoid (Botulin E toxoid) . . . . . . . . . . . . . . 14 Clostridium tetani toxoid (Tetanus toxoid) . . . . . . . . . . . . . . . . . . . . . 14 Coagulation factor IX (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Collagen Type I (human, bovine, pig, sheep, dog, goat) . . . . . . . . 10 Collagen Type III (human, dog, rat, kangaroo) . . . . . . . . . . . . . . . . 10 Collagen Type V (human, dog, sheep, pig, kangaroo, rabbit, bovine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Collectin-43 (bovine, CL-43) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Complement component C1-inhibitor (human, C1-INH) . . . . . . . . 11 Complement component C1s (human, pro- and activated enzyme) . . . . . . . . . . . . . . . . . . . . . . . . . 11 Complement component C2 (human) . . . . . . . . . . . . . . . . . . . . . . . . . 11 Complement component C3 (human) . . . . . . . . . . . . . . . . . . . . . . . . . 11
17
Complement component C3 (human), β-chain genetic variant . . . 11 Complement component C3 (rat) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Complement component C3a/C3a desArg (human) . . . . . . . . . . . . 11 Complement component C4 (human) . . . . . . . . . . . . . . . . . . . . . . . . . 11 Complement component C5 (human) . . . . . . . . . . . . . . . . . . . . . . . . . 11 Complement component C5a/C5a (desArg) anaphylatoxin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Complement component C5b-9 (human) . . . . . . . . . . . . . . . . . . . . . 12 Complement component C9 (human) . . . . . . . . . . . . . . . . . . . . . . . . 12 Complement factor B (caiman) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Complement factor B (chicken) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Complement factor B (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Complement factor D (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Complement factor H (human, ß1H-globulin) . . . . . . . . . . . . . . . . . 12 Complement factor I (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Conglutinin (bovine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Corynebacterium diphtheriae toxoid (Diphtheria toxoid) . . . . . . . . 14
Diagnostics
Factor IX (human, Christmas factor) . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Fetoprotein (human, AFP) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Fibrinogen (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Fibronectin (bovine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Fibronectin (bovine, human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Fibronectin (bovine, human, chicken) . . . . . . . . . . . . . . . . . . . . . . . . 10 Fibronectin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Ficolin-H (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Ficolin-L (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Ficolin-M (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
G Gastric inhibitory polypeptide (human, GIP) . . . . . . . . . . . . . . . . . . 13 Gc-globulin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Gelsolin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Ghrelin (human, rat) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Gliadin peptide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Glucagon-like peptide-1 (GLP-1(1-36)amide, N-terminal-extension specific) . . . . . . . . . . . 13 Glucagon-like peptide-1 (GLP-1(7-36)amide, C-terminal specific) . . . . . . . . . . . . . . . . . . . . . 13 Glucagon-like peptide-1 (GLP-1(7-37) and GLP-1(7-36)amide, N-terminal specific) . . . . . . 13 Glucagon-like peptide-1 (GLP-1(9-37) and GLP-1(9-36)amide, N-terminal specific) . . . . . . . . . . . . . . . . . . . . . . 13 Glucagon-like peptide-1 (GLP-1, Mid-molecule specific) . . . . . . 13
Glucagon-like peptide-1 (GLP-1, non-amidated (-Arg-Gly), C-terminal specific) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Glucagon-like peptide-2 (human, GLP-2) . . . . . . . . . . . . . . . . . . . . 13 Glycodelin A (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Glycoprotein-340 (human, gp-340) . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
H Haptoglobin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Hemopexin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 hCG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 H-Ficolin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Hirudin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 HNL (human neutrophil lipocalin) . . . . . . . . . . . . . . . . . . . . . . 3, 5, 6, 14 HSA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 HSA, denatured . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 hSP-A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 hSP-D . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Human IgE (non-immune) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
I IgE (human, non-immune) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 IgG/k control antibody . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Immunoglobulin heavy chain (chicken, IgY) . . . . . . . . . . . . . . . . . . . 15 Immunoglobulin light chain (rat, κ chain) . . . . . . . . . . . . . . . . . . . . . 15 Influenza A virus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14, 15 Influenza B virus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14, 15
L LDL, (human, MDA-treated) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Leptin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 L-Ficolin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Lipocalin-2 (human, dog, mouse, pig, rat) . . . . . . . . . . . . . 3, 5, 6, 14
M Mannan-binding lectin (chicken, MBL) . . . . . . . . . . . . . . . . . . . . . . . 12 Mannan-binding lectin (human, horse, pig, MBL) . . . . . . . . . . . . . 12 Mannan-binding lectin (human, MBL) . . . . . . . . . . . . . . . . . . . . . . 9, 12 Mannan-binding lectin (rat, MBL) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 MBL standard serum (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 MBL Oligomer deficient serum (human) . . . . . . . . . . . . . . . . . . . . . . 16 MDA treated low-density lipoprotein (human, LDL) . . . . . . . . . . . . 16 M-Ficolin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 MHC class I α chain (chicken) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 MHC class II β chain (chicken) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Monkey NGAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 14 Mouse NGAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 14 Mycobacterium tuberculosis, Ag85 . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Mycobacterium tuberculosis, ESAT-6 . . . . . . . . . . . . . . . . . . . . . . . . 15 Mycobacterium tuberculosis, L-alanine dehydrogenase (Ald) . . . 15
N Neuropeptide Y (human, rat, mouse, NPY) . . . . . . . . . . . . . . . . . . . 13 NGAL (dog, neutrophil gelatinase-associated lipocalin) . . . . . . . . . 7, 14 NGAL (human, neutrophil gelatinase-associated lipocalin) . 3, 5, 6, 14 NGAL (monkey, neutrophil gelatinase-associated lipocalin) . . . . . 7, 14 NGAL (mouse, neutrophil gelatinase-associated lipocalin) . . . . . . 7, 14 NGAL (pig, neutrophil gelatinase-associated lipocalin) . . . . . . 7, 14 NGAL (rat, neutrophil gelatinase-associated lipocalin) . . . . . . . 7, 14 Nitrobacter hamburgensis nitrite oxidoreductase . . . . . . . . . . . . . 15
O Ovalbumin (chicken) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Ovalbumin (chicken, denatured) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
P PAI-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Pancreatic polypeptide (human, PP) . . . . . . . . . . . . . . . . . . . . . . . . 13 Peptide histidine-methionine (human, PHM) . . . . . . . . . . . . . . . . . . 14 Peptide YY (human, PYY) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Perlecan (bovine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Pig NGAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 14 Placental protein 14 (human, PP14, glycodelin A) . . . . . . . . . . . . . . 14 Plasminogen activator inhibitor type 1 (human, PAI-1) . . . . . . . . . 15 Pneumolysin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Poliovirus type 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Poliovirus type 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Poliovirus type 3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Pregnancy-associated plasma protein A (human, PAPP-A) . . . . . 14 Procollagen type I C-terminal propeptide (human, PICP) . . . . . . . 14 Procollagen type IIA N-terminal propeptide (human, PIIANP) . . . 14 Properdin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Protein C (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Protein S (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
R Rat NGAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 14
S Streptolysin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Surfactant protein A (human, hSP-A) . . . . . . . . . . . . . . . . . . . . . . . . . 11 Surfactant protein D (human, hSP-D) . . . . . . . . . . . . . . . . . . . . . . . . . 11 Siderocalin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3, 5, 6, 7, 14
T Tetanus toxoid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Tetranectin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 The NGAL TestTM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Thioguanine (2-amino-6-mercaptopurine) . . . . . . . . . . . . . . . . . . . . 15 Thrombin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Thrombospondin I (bovine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Tissue plasminogen activator (human, tPA) . . . . . . . . . . . . . . . . . . 15 Trypsin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Tumor necrosis factor α (human, TNF-α) . . . . . . . . . . . . . . . . . . . . . . 14
U Urokinase plasminogen activator (human, uPA) . . . . . . . . . . . . . . . 15 Urokinase plasminogen activator receptor (human, uPAR) . . . . . 15
V Vasoactive intestinal peptide (human, bovine, porcine, rat, VIP) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Vitamin-D binding protein (human) . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Vitronectin (bovine, horse, rabbit) . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Vitronectin (bovine, sheep) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Vitronectin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Vitronectin (human, dog, cat, rabbit, bovine) . . . . . . . . . . . . . . . . . 10 Vitronectin (human, dog, cat, sheep) . . . . . . . . . . . . . . . . . . . . . . . . . 10 von Willebrand factor (human, vWf) . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
18 Diagnostics
Ordering information Products should be ordered from your local BioPorto Diagnostics distributor, please see www.bioporto.com/how_to_buy. If there is no distributor in your country, please order directly from BioPorto Diagnostics. BioPorto Diagnostics A/S Grusbakken 8 DK-2820 Gentofte Denmark VAT number DK-1864 5882 Phone (+45) 4529 0000 Fax (+45) 4529 0001 Mail info@bioporto.com Web www.bioporto.com
Terms and conditions Returns No returns can be accepted without prior written approval by the ordering channel (distributor or BioPorto Diagnostics A/S). Only unopened merchandise that has been handled and stored as prescribed can be returned. No return of custom manufactured products will be authorized if the product meets the specifications agreed upon prior to shipment. Alternate right BioPorto Diagnostics A/S reserves the right to change product specifications (e.g. buffer system) to maximize product quality. Storage Directions given on an individual datasheet or label are an integral part of these terms and conditions and must be strictly followed. Reservation of title Unless otherwise marked, all products are for research use or further manufacture only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. Product codes: GAU*, MON* and DIA 011-01B, are not for further manufacture either. Products sold for in vitro diagnostic use are CE-marked and comply with EU Directive 98/79/EC and Canadian Medical Device Regulations. In vitro diagnostic products are available in selected countries, see www.bioporto.com for availability in your country. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics be responsible for loss of profits or indirect consequential losses resulting from use of its products. For more information contact your local distributor or BioPorto Diagnostics A/S.
19
Diagnostics
BioPorto develops and markets antibodies and antibody-based products, including tests to diagnose human disease, both for the benefit of individual patients and to promote efficiency in the health sector. The Company’s developments include a test (NGAL) to diagnose and monitor acute kidney damage. www.bioporto.com
BioPorto Diagnostics A/S Grusbakken 8 DK-2820 Gentofte Denmark
Phone Fax E-mail Web
(+45) 4529 0000 (+45) 4529 0001 info@bioporto.com www.bioporto.com www.ngal.com 20 Diagnostics
70004/032011/e
Diagnostics